IRIS
CALVISI, Diego Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.517
EU - Europa 2.382
AS - Asia 1.522
OC - Oceania 27
AF - Africa 23
SA - Sud America 17
Continente sconosciuto - Info sul continente non disponibili 12
Totale 8.500
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.474
UA - Ucraina 931
CN - Cina 837
SG - Singapore 566
DE - Germania 375
IT - Italia 358
SE - Svezia 276
FI - Finlandia 140
GB - Regno Unito 84
FR - Francia 76
BE - Belgio 48
CA - Canada 41
CZ - Repubblica Ceca 39
TR - Turchia 32
AU - Australia 25
DZ - Algeria 21
IN - India 19
ID - Indonesia 17
KR - Corea 15
RO - Romania 14
BR - Brasile 12
IR - Iran 12
EU - Europa 10
AT - Austria 6
BD - Bangladesh 6
RU - Federazione Russa 6
ES - Italia 4
NL - Olanda 4
HK - Hong Kong 3
HU - Ungheria 3
IL - Israele 3
JP - Giappone 3
LT - Lituania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
DK - Danimarca 2
IQ - Iraq 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
PL - Polonia 2
AL - Albania 1
AR - Argentina 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
IE - Irlanda 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MA - Marocco 1
MX - Messico 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
VE - Venezuela 1
Totale 8.500
Salva come PNG Salva come JPEG
Città #
Chandler 1.428
Jacksonville 526
Singapore 420
Princeton 377
Nanjing 218
Wilmington 169
Sassari 167
Ann Arbor 162
Dearborn 148
Beijing 96
Boardman 89
Ashburn 80
Nanchang 77
Woodbridge 54
Santa Clara 53
Shenyang 53
Brussels 47
Hebei 46
Changsha 45
New York 43
Tianjin 42
Jinan 37
Brno 35
Jiaxing 35
Norwalk 32
Toronto 31
Andover 29
Falls Church 29
Izmir 28
Mountain View 28
Dallas 23
Munich 23
Ningbo 22
Algiers 21
Hangzhou 21
Guangzhou 20
Kunming 20
Helsinki 19
Zhengzhou 19
San Francisco 18
Leawood 15
Augusta 14
San Mateo 14
Seoul 14
Taizhou 14
Auburn Hills 12
Los Angeles 12
Monmouth Junction 12
Ardabil 10
Houston 10
Melbourne 10
Lanzhou 9
Changchun 8
Fairfield 8
Haikou 8
Rome 8
Lappeenranta 7
Romola 7
Shanghai 7
Washington 7
Milan 6
Berlin 5
Canberra 5
Frankfurt am Main 5
Ottawa 5
Chicago 4
Hanover 4
London 4
Marrùbiu 4
Olomouc 4
Seattle 4
Tappahannock 4
Vienna 4
West Jordan 4
Cagliari 3
Central 3
Florence 3
Grézieu-la-varenne 3
Messina 3
Perugia 3
Stockholm 3
Torino 3
Wuxi 3
Alghero 2
Auckland 2
Bari 2
Beinasco 2
Cambridge 2
Città Di Castello 2
Como 2
Dhaka 2
IJsselstein 2
Madrid 2
Montreal 2
Mumbai 2
Newark 2
Nuremberg 2
Orani 2
Raleigh 2
Redwood City 2
Totale 5.159
Salva come PNG Salva come JPEG
Nome #
Underserved populations and bacterial and protozoal sexually transmitted infections: a lost health-care opportunity 93
Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma 93
The burden of HIV-Associated neurocognitive disorder (HAND) in post-HAART era: Amultidisciplinary review of the literature 90
Correlation of c-myc overexpression and amplification with progression of preneoplastic liver lesions to malignancy in the poorly susceptible Wistar rat strain 87
Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-kappa B and Mat1A genes in the early stages of rat liver carcinogenesis 84
Role of HSP90,CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer 80
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans 76
Alterations of methionine metabolism in hepatocarcinogenesis: the emergent role of glycine N-methyltransferase in liver injury 76
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumor formation in mice via AKT2/mTORC1 cascade. 72
Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis 70
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans 69
Hydrodynamic transfection for generation of novel mouse models for liver cancer research. 68
Analysis of loss of heterozygosity in neoplastic nodules induced by diethylnitrosomine in the resistant BFF1 rat strain 68
Frequent loss of heterozygosity at the Hcr1 (Hepatocarcinogenesis resistance) locus on chromosome 10 in primary hepatocellular carcinomas from LFF1 rat strain 67
Application of comparative functional genomics to identify best-fit mouse models to study human cancer 67
4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras protooncogenes 66
Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease 66
Experimental models to define the genetic predisposition to liver cancer 65
[11C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. 64
Deregulation of methionine metabolism as determinant of progression and prognosis of hepatocellular carcinoma 64
Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines 64
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis 63
Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells 63
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans 63
MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes 62
5' Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon tetrachloride intoxication 61
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice 60
Implication of Bcl 2 family genes in basal and D amphetamine induced apoptosis in preneoplastic and neoplastic rat liver lesions 60
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B 60
The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans 60
Activation of β-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice. 60
Lessons from rare tumors: Hepatic lymphoepithelioma-like carcinomas 60
Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital 60
Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis 59
Phenotypic reversion of rat neoplastic liver nodules is under genetic control 58
Identification and chromosome mapping of loci predisposing to colorectal cancer that control Wnt/b-catenin pathway and progression of early lesions in the rat 58
Beta catenin or genomic instability define two categories of liver cancer in transgenic mice 58
Dual-Specific Phosphatase 1 Ubiquitination in Extracellular Signal-Regulated Kinase-Mediated control of Grawth in Human Hepatocellular Carcinoma 58
Identification of genetic loci controlling hepatocarcinogenesis on rat chromosomes 7 and 10 57
Classification and survival prediction of hepatocellular carcinoma by gene expression profiling 57
Altered methionine metabolism and global DNA methylation in liver cancer: Relationship with genomic instability and prognosis 57
An infernal cross-talk between oncogenic β-catenin and c-Met in hepatocellular carcinoma: Evidence from mouse modeling 57
Hepatocarcinogenesis following pancreatic islet transplantation in streptozotocin- and autoimmune-diabetic rats 57
Polygenic control of hepatocarcinogenesis in Copenhagen x F344 rats 56
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer 56
p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. 56
Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma 56
Chromosome mapping of multiple loci affecting the genetic predisposition to rat liver carcinogenesis 56
Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis 56
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells 56
SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis 55
Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma 55
Long-term dehydroepiandrosterone and 16alfa-fluoro-5-androsten-17-one administration enhances DNA synthesis and induces expression of c-fos and c-Ha-ras in a selected population of preneoplastic lesions in liver of diethylnitrosamine-initiated rats 55
Disregulation of E-cadherin in transgenic mouse models of liver cancer 55
Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease 54
Activation of the canonical Wnt/Beta-catenin pathway confers growth advantages in c-My/E2F1 transgenic mouse model of liver cancer 53
Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide 53
Transferrin and transferrin receptor gene expression and iron upteke in hepatocellular carcinoma in the rat 52
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma 52
Role of transcriptional and postttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. 52
The dark side of the moon: AKT as a tumor suppressor in the liver? 52
Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. 52
Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma 52
AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. 52
Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value 51
Disregulation of DNA repair pathways in TGF-alfa/c-myc transgenic mouse model of accelerated hepatocarcinogenesis 51
Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis. 51
Mapping a sex-hormone sensitive gene determining female resistance to liver carcinogenesis in a congenic F344 BN-Hcs4 rat. 51
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade 51
Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations 51
Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer 50
Epigenetics of liver cancer progression: Role of transcriptional and post-transcriptional regulation of methionine adenosyltransferases in liver cancer progression. 50
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC 50
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma 50
SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer 50
Non-functioning gastroenteropancreatic (GEP) tumors: a 111In-Pentetreotide SPECT/CT diagnostic study. 50
Accomplices in crime: The diabolical liaison between protein tyrosine phosphatase 1B and ras in hepatocellular carcinoma 49
AKT/mTOR activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. 49
Combined treatment with MEK and mTOR inhibitors is effective in in Vitro and in Vivo models of hepatocellular carcinoma 49
Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control 48
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models 48
Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. 48
Sulfatase 1: A new Jekyll and Hyde in hepatocellular carcinoma? 48
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells 48
Activation of Beta-Catenin During Hepatocarcinogenesis in Transgenic Mouse Models: Relationships to Phenotype and Tumor Grade 48
Programmed death ligand 1 expression in hepatocellular carcinoma: A prognostic marker and therapeutic target for liver cancer? 47
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver 47
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice 47
Aurora A regulates prometaphase progression by inhibiting the ability of RASSF1A to suppress APC-Cdc20 activity 47
Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype 47
NORE1A Tumor Suppressor Candidate Modulates p21CIP1 via p53 46
Bmi1 is required for hepatic progenitor cell expansion and liver tumor development. 46
Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: Novel insights from interspecies comparison 46
SNAI1 promotes the cholangiocellular phenotype, but not epithelial-mesenchymal transition, in a murine hepatocellular carcinoma model 46
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice 46
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans 46
DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma? 45
Molecular mechanisms of liver carcinogenesis in transgenic mouse models of liver cancer 45
EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. 44
Loss of pten synergizes with c-met to promote hepatocellular carcinoma development via mTORC2 pathway 44
Totale 5.723
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.851
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.851
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020947 0 0 0 0 133 129 264 25 161 64 165 6
2020/20211.446 143 5 243 11 144 101 189 8 225 215 134 28
2021/20221.077 125 9 6 10 23 36 53 65 110 55 122 463
2022/20232.421 255 222 143 409 195 384 3 248 376 10 94 82
2023/2024557 116 37 16 25 103 25 3 57 0 12 48 115
2024/2025834 43 52 366 170 203 0 0 0 0 0 0 0
Totale 8.726